Short Interest in Nutriband Inc. (NASDAQ:NTRB) Increases By 37.7%

Nutriband Inc. (NASDAQ:NTRB) was the target of a significant growth in short interest in February. As of February 15th, there was short interest totalling 361,000 shares, a growth of 37.7% from the January 31st total of 262,100 shares. Based on an average daily volume of 202,200 shares, the short-interest ratio is currently 1.8 days. Approximately 7.1% of the company’s stock are sold short.

Nutriband Stock Down 0.1 %

Shares of Nutriband stock traded down $0.01 on Wednesday, reaching $6.95. The company’s stock had a trading volume of 24,870 shares, compared to its average volume of 82,640. Nutriband has a 52 week low of $2.22 and a 52 week high of $11.78. The firm’s fifty day simple moving average is $6.22 and its two-hundred day simple moving average is $5.62. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $77.19 million, a price-to-earnings ratio of -9.79 and a beta of 1.08.

Nutriband (NASDAQ:NTRB) last issued its quarterly earnings data on Tuesday, December 3rd. The company reported ($0.12) EPS for the quarter. Nutriband had a negative return on equity of 54.49% and a negative net margin of 338.51%. Equities analysts anticipate that Nutriband will post -0.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Noble Financial began coverage on Nutriband in a research report on Wednesday, January 22nd. They set an “outperform” rating and a $13.00 price objective for the company.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Nutriband stock. Geode Capital Management LLC lifted its stake in shares of Nutriband Inc. (NASDAQ:NTRB) by 7.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 62,435 shares of the company’s stock after acquiring an additional 4,372 shares during the quarter. Geode Capital Management LLC owned approximately 0.56% of Nutriband worth $294,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.70% of the company’s stock.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.